This page is the campaign hub for the suits that Genentech, Inc. and Hoffmann-La Roche Inc., joined in three of them by PTC Therapeutics, Inc., have filed over abbreviated new drug applications (ANDAs) for generic versions of EVRYSDI (risdiplam). All six suits listed here are in the District of New Jersey, and each alleges infringement under 35 U.S.C. § 271(e)(2)(A) by the submission of an ANDA. The complaints say Genentech is a Delaware corporation with its principal place of business in South San Francisco, California, and holds the exclusive right to sell, distribute, and market EVRYSDI in the United States, and that Hoffmann-La Roche Inc. is a New Jersey corporation with its principal place of business in Little Falls, New Jersey, that helped develop and obtained FDA approval to market EVRYSDI. The complaints PTC joins say PTC is a Delaware corporation with its principal place of business in Warren, New Jersey. These are the plaintiffs' allegations.
The drug and the patents
The complaints describe EVRYSDI as a survival of motor neuron 2 splicing modifier indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. They say Genentech holds New Drug Application No. 213535 for EVRYSDI, which the 2024 and 2025 complaints describe as risdiplam provided as a powder for constitution to a 0.75 mg/mL solution, and the 2026 complaints say Genentech holds New Drug Application No. 219285 for EVRYSDI tablets, each containing 5 mg of risdiplam. The four suits filed from November 2024 through October 2025 concern ANDAs for a generic version of EVRYSDI for oral solution; the two suits filed in 2026 concern ANDAs for a generic version of EVRYSDI tablets.
Seven patents are asserted across the suits. The complaints allege that Roche and PTC jointly own U.S. Patents 9,586,955, 9,969,754, and 11,827,646, each titled Compounds for Treating Spinal Muscular Atrophy, which issued on March 7, 2017, May 15, 2018, and November 28, 2023. They allege that Roche owns U.S. Patent 11,534,444, titled Treatment of SMA, issued December 27, 2022; U.S. Patent 11,938,136, titled Compositions for Treating Spinal Muscular Atrophy, issued March 26, 2024; U.S. Patent 12,122,789, titled Forms of Pyrido[1,2-a]pyrimidin-4-one Derivatives, Its Formulation and Its Process of Making, issued October 22, 2024; and U.S. Patent 12,350,273, also titled Treatment of SMA, issued July 8, 2025. The complaints allege that Roche has licensed its rights under each of these patents to Genentech, and each complaint alleges that the patents it asserts are listed in FDA's Orange Book in connection with EVRYSDI, or, in the 2026 complaints, EVRYSDI tablets. PTC joins the counts on the '955, '754, and '646 patents.
The oral solution suits
Genentech, Inc. v. Natco Pharma Limited, No. 2:24-cv-10567, filed November 18, 2024, by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. against Natco Pharma Limited, Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc., concerns Natco's ANDA No. 219848 and Zydus's ANDA No. 219902. Counts I to V assert the '955, '754, '444, '646, and '136 patents against Natco, and Counts VI and VII assert the '444 and '136 patents against the Zydus defendants. The complaint says the plaintiffs received notice of the Natco ANDA by a letter dated October 10, 2024, and that Genentech and Roche received notice of the Zydus ANDA by a letter dated October 21, 2024. A first amended complaint filed February 12, 2026 adds Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. as defendants, pleads Counts I to V against Natco and Sun, and alleges, on information and belief, that Natco, Sun Ltd., and Sun Inc. acted in concert to prepare and file the Natco ANDA.
Genentech and Hoffmann-La Roche Inc. filed the next three suits. Genentech, Inc. v. Natco Pharma Limited, No. 2:24-cv-11308, filed December 19, 2024, asserts the '789 patent against Natco Pharma Limited over the Natco ANDA, after a notice letter dated November 20, 2024. The claim construction opinion says Genentech and Roche filed a first amended complaint in that case on February 12, 2026 against Natco, Sun Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries, Inc., alleging one count of infringement of the '789 patent. Genentech, Inc. v. Zydus Lifesciences Global FZE, No. 2:25-cv-01521, filed February 27, 2025, asserts the '789 patent against Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc. over the Zydus ANDA, after a notice letter dated January 14, 2025. Genentech, Inc. v. Natco Pharma Limited, No. 2:25-cv-17100, filed October 31, 2025, asserts the '273 patent against Natco Pharma Limited in Count I and against the three Zydus defendants in Count II, over the same two ANDAs; it says Genentech and Roche received notice of the Natco ANDA by a letter dated September 17, 2025. The docket of No. 2:25-cv-17100 shows an amended complaint filed February 12, 2026.
Consolidation and claim construction
In a stipulation and order signed March 25, 2025, the court consolidated Nos. 2:24-cv-11308 and 2:25-cv-01521 with No. 2:24-cv-10567, the lead action, for all pretrial purposes. According to the October 23, 2026 claim construction opinion, the court later also consolidated No. 2:25-cv-17100 into Consol. No. 2:24-cv-10567 for all pretrial purposes. Text orders entered April 20, 2026 reassigned Nos. 2:24-cv-11308 and 2:25-cv-01521 to Judge Jennifer Choe-Groves of the U.S. Court of International Trade, who signed the claim construction opinion sitting by designation.
In the consolidated case, the court adopted the parties' agreed constructions of "effective amount" in the '955 patent and "therapeutically effective amount" in the '754 and '646 patents in a February 13, 2026 order. After a September 17, 2026 hearing, it construed "crystalline Form A" in the '789 patent in an October 23, 2026 opinion and order as the specification defines it, "the crystalline anhydrous polymorphic Form A of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one," and declined the defendants' proposal to require all of the characteristics the specification assigns to Form A. The opinion notes that the defendants reserved indefiniteness arguments under 35 U.S.C. § 112 for summary judgment or trial.
The tablets suits
Genentech, Inc. v. Zenara Pharma Private Limited, No. 2:26-cv-06555, filed June 4, 2026, by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. against Zenara Pharma Private Limited, Biophore Pharma Inc., and Biophore India Pharmaceuticals Private Limited, concerns Zenara's ANDA No. 221422 for a generic version of EVRYSDI tablets, after a notice letter dated April 23, 2026. Its six counts assert the '955, '754, '444, '646, '789, and '273 patents, one per count. The complaint alleges, on information and belief, that Biophore Pharma Inc. and Biophore India Pharmaceuticals Private Limited acted in concert with Zenara to prepare and file the ANDA.
Genentech, Inc. v. Zydus Lifesciences Global FZE, No. 2:26-cv-14713, filed November 13, 2026, by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. against Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc., concerns ANDA No. 222036 for a generic version of EVRYSDI tablets, after a notice letter dated October 2, 2026. Its five counts assert the '754, '646, '444, '789, and '273 patents, one per count. The complaint alleges, on information and belief, that Zydus did not include a Paragraph IV certification as to the '955 patent and instead included a Paragraph III certification that it will not market its tablets until after that patent expires.
The proceedings
The table lists each suit in order of filing, with the status each docket shows through November 16, 2026. All six are in the District of New Jersey. Patents appear by their last three digits; the full numbers are above. The patents listed are those each complaint's counts assert against each defendant group, with the first amended complaints in Nos. 2:24-cv-10567 and 2:24-cv-11308 extending the Natco counts to Sun.
| No. | Filed | Plaintiffs | Defendants | ANDA | Patents | Status on the docket |
|---|---|---|---|---|---|---|
| 2:24-cv-10567 (lead) | November 18, 2024 | Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. | Natco Pharma Limited, Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc.; Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. added by the first amended complaint | Natco No. 219848 and Zydus No. 219902 (oral solution) | Natco and Sun: '955, '754, '444, '646, '136. Zydus: '444, '136. | Lead case of the consolidated action. First amended complaint filed February 12, 2026; order adopting agreed constructions, ECF No. 105, entered February 13; answer to the first amended complaint by Natco and Sun filed March 5; scheduling order entered July 29; claim construction hearing held September 17; opinion and order on claim construction, ECF No. 184, filed October 23, 2026. |
| 2:24-cv-11308 | December 19, 2024 | Genentech, Inc. and Hoffmann-La Roche Inc. | Natco Pharma Limited. The claim construction opinion says the first amended complaint, filed February 12, 2026, names Natco, Sun Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries, Inc. | Natco No. 219848 (oral solution) | '789 | Answer by Natco Pharma Limited filed February 21, 2025; consolidated with No. 2:24-cv-10567 for all pretrial purposes by stipulation and order of March 25, 2025; reassigned to Judge Jennifer Choe-Groves April 20, 2026. |
| 2:25-cv-01521 | February 27, 2025 | Genentech, Inc. and Hoffmann-La Roche Inc. | Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc. | Zydus No. 219902 (oral solution) | '789 | Consolidated with No. 2:24-cv-10567 for all pretrial purposes by stipulation and order of March 25, 2025; reassigned to Judge Jennifer Choe-Groves April 20, 2026. |
| 2:25-cv-17100 | October 31, 2025 | Genentech, Inc. and Hoffmann-La Roche Inc. | Natco Pharma Limited, Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc. | Natco No. 219848 and Zydus No. 219902 (oral solution) | Natco: '273. Zydus: '273. | Answer and counterclaim filed December 4, 2025; answer filed December 9; answer to counterclaim filed December 18, 2025; amended complaint filed February 12, 2026. The claim construction opinion says the court consolidated this case into No. 2:24-cv-10567 for all pretrial purposes. |
| 2:26-cv-06555 | June 4, 2026 | Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. | Zenara Pharma Private Limited, Biophore Pharma Inc., and Biophore India Pharmaceuticals Private Limited | Zenara No. 221422 (tablets) | '955, '754, '444, '646, '789, '273 | Answer and counterclaim filed August 24, 2026; answer to counterclaim filed September 14; scheduling orders entered October 23 and October 26. |
| 2:26-cv-14713 | November 13, 2026 | Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. | Zydus Lifesciences Global FZE, Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc. | Zydus No. 222036 (tablets) | '754, '646, '444, '789, '273 | Complaint filed November 13, 2026. |
What to watch next
Watch for further proceedings in Consol. No. 2:24-cv-10567 after the October 23, 2026 claim construction opinion, for discovery under the scheduling orders in No. 2:26-cv-06555, and for the Zydus defendants' answer, counterclaims, or a Rule 12 motion in No. 2:26-cv-14713. Any of these cases can end at any time, including by settlement or voluntary dismissal.